glp 1 glucagon dual agonist The current significance and prospects for the use of receptor agonism GLP-1/Glucagon Mazdutide vs tirzepatide: comparing dual-agonist

Semaglutide was removed in February 2025

GLP-1s claimed the top two spots in 2024 drug spending and accounted for more than one-third of the top 10 drugs overall.

Navigating the world of weight loss supplements can be daunting, with countless products promising quick results.

Looking ahead, the influence of US policy and Most Favoured Nation (international reference) pricing will remain a central trend that shaped obesity care in 2025 and will continue to do so into 2026 and beyond

Starting in mid-2026, Medicare will begin covering these drugs for select patient groups and state Medicaid programs have the option to adopt similar coverage at these discounted rates

Recently, the Food and Drug Administration officially approved semaglutide for the treatment of metabolic dysfunction-associated steatohepatitis in adults with moderate-to-advanced fibrosis